Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 18

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 18
---
 OF DIRECTORS IN RISK OVERSIGHT
The Audit Committee is primarily responsible for overseeing our risk management processes on behalf of our board of directors. The Audit Committee receives reports from management periodically regarding our assessment of risks. In addition, the Audit Committee reports regularly to our board of directors, which also considers our risk profile. The Audit Committee and our board of directors focus on the most significant risks we face and our general risk management strategies. The Compensation Committee evaluates risks associated with and potential consequences of our compensation policies and practices and assesses whether such risks and consequences as may be mitigated by any other compensation policies and practices, are reasonably likely to have a material adverse effect on the Company. While our board of directors oversees our risk management, management is responsible for day-to-day risk management processes. Our board of directors expects management to consider risk and risk management in each business decision, to proactively develop and monitor

#### 22Castle Biosciences 2025 Proxy Statement
| Information Regarding the Board of Directors and Corporate Governance |

risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the Audit Committee and our board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our board of directors’ leadership structure, which also emphasizes the independence of our board of directors in its oversight of its business and affairs, supports this approach.

### INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS
Our board of directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides the membership of each such committee as of the date of this Proxy Statement and the total number of committee meetings held during the fiscal year ended December 31, 2024:

| Name                   |     | Audit |     | Compensation(1) |     | Nominating and Corporate Governance |
| Kimberlee S. Caple     |     |     M |     |                 |     |                                   M |
| G. Bradley Cole        |     |     C |     |               M |     |                                     |
| Derek J. Maetzold      |     |       |     |                 |     |                                     |
| Ellen Goldberg         |     |       |     |               M |     |                                   M |
| Miles D. Harrison      |     |       |     |               C |     |                                   M |
| Tiffany P. Olson       |     |     M |     |                 |     |                                   C |
|